Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting
Voyager Therapeutics, Inc. (VYGR)
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.voyagertherapeutics.com
Company Research
Source: GlobeNewswire
Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson’s Disease Treatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours at 12 Months in Patients with Parkinson’s Disease SAN DIEGO and CAMBRIDGE, Mass., May 05, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson’s disease who participated in the open-label trial to evaluate the safety and efficacy of VY-AADC and to further assess the posterior (i.e., from the back of the head) surgical delivery approach. These Phase I results are being presented today as a poster presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting. Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disorder that affects appr
Show less
Read more
Impact Snapshot
Event Time:
VYGR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYGR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYGR alerts
High impacting Voyager Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VYGR
News
- Voyager Therapeutics, Inc. (NASDAQ: VYGR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR) [Yahoo! Finance]Yahoo! Finance
- Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High? [Yahoo! Finance]Yahoo! Finance
- Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at Wedbush. They set an "outperform" rating and a $11.00 price target on the stock.MarketBeat
VYGR
Earnings
- 11/12/24 - Beat
VYGR
Sec Filings
- 12/23/24 - Form 144
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- VYGR's page on the SEC website